Author | Jane de Lartigue, PhD | OncLive

Author | Jane de Lartigue, PhD


HRD Testing Heralds a New Biomarker, but Questions Linger

August 05, 2020


Homologous recombination, one of the major mechanisms of defective DNA repair, has emerged as a bona fide therapeutic target, yet its optimal use as a biomarker for patient selection remains a clouded scientific question.

CLR 131 Leads a New Generation of Lipid-Based Cancer Drug Delivery Systems

July 19, 2020


A novel compound that uses abundant lipids in cancer cell membranes to deliver a radioisotope to the tumor environment shows early signs of efficacy in a range of B-cell malignancies.

New Strategies for Targeting CD38 in Multiple Myeloma Take Root

June 26, 2020


During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

A New Generation of Drugs Targeting PD-1/PD-L1 Takes Shape in Oncology

June 08, 2020


Over the past decade, immunotherapy has established itself as one of the pillars of cancer treatment, thanks in large part to the success of monoclonal antibodies that target the immune checkpoint protein PD-1 or its main ligand, PD-L1.